| |
October 16-18, 2023 | Boston, MA
|
|
Today's Big NewsJul 18, 2023 |
| By Nick Paul Taylor Novartis has dumped its secretive, high-risk, high-reward obesity candidate after emerging from a phase 2 trial with lackluster efficacy. The Swiss drugmaker disclosed the termination alongside news that it is stopping development of a phase 3 pancreatic cancer candidate “based on benefit-risk assessment.” |
|
|
|
| July 18-19, 2023 | Jersey City, NJ |  |
|
|
By Gabrielle Masson Pfizer and Flagship Pioneering have each put down $50 million to build a new pipeline of 10 programs, with the Big Pharma offering Flagship and its bioplatform companies the chance to earn up to $700 million in biobucks for each program that makes it to market. |
By Max Bayer AstraZeneca is ending a partnership with Pieris for the biotech's asthma medication, forcing the company to restrategize and lay off 70% of the team. The Big Pharma had halted dosing in ongoing clinical trials testing elarekibep after seeing nonclinical toxicology data. |
Sponsored by Altasciences Optimize Your Drug Development Timeline With This Dosage Form Can you name five benefits of using liquid-filled, hard-shell capsules in drug development over other solid oral dosage forms? Find out! |
|
BioIVT can guide you to the right solution for your specific R&D goals, optimizing the speed, cost and data deliverables to exactly what you need. Expert ADME Services >> 
|
|
By Nick Paul Taylor Neurogene has struck deals to fund its pipeline of gene therapies into the second half of 2026, agreeing to merge with the floundering, Nasdaq-listed Neoleukin Therapeutics and persuading investors to pump $95 million into the combined company. |
By Max Bayer Neumora is gearing up for a trio of phase 3 trials for its depression med after posting encouraging phase 2 data. The well-financed biotech spun out of Atlas, now with a new CEO with Big Pharma pedigree, is fending off outside interest. |
By Max Bayer Sanofi is taking another dip in Scribe's CRISPR pool, inking a new in vivo gene editing partnership worth more than $1.2 billion. The two companies said that one focus of the development pact will be treating sickle cell disease. |
By Gabrielle Masson Westlake Village BioPartners has launched its third fund, a $450 million vault for developing early-stage, next-gen biotechs in Los Angeles and beyond. |
By Fraiser Kansteiner Sanofi’s immunization scheme is starting to fall into place thanks to an approval that could propel it and its partner AstraZeneca to the front lines of the RSV scene. |
By Joseph Keenan Alcanza Clinical Research acquired Accel Research Site Network and its 22 trial sites located in the Southeast U.S. in a move to expand its footprint. |
By Fraiser Kansteiner In tandem with Taiwan’s Food and Drug Administration, GSK this week initiated a recall of two batches of its severe asthma injection Nucala after glass fragments were found in a vial of the drug. |
By Kevin Dunleavy With the acquisition of two commercial medicines from Travere Therapeutics, liver disease specialist Mirum Pharmaceuticals has gone from a company with one product to having a “franchise,” according to CEO Chris Peetz. Now—in addition to its potential blockbuster Livmarli—Mirum has gained bile acid treatments Cholbam and Chenodal for $210 million upfront and $235 million in potential milestones. |
By Heather Landi Teladoc is ramping up its investment in AI to infuse innovation into its telehealth solution for hospitals. The largest telehealth company is tapping into its two-year partnership with tech giant Microsoft to integrate AI and speech recognition tech into its Solo virtual care platform. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about how big data can inform policy. Also under discussion is the role of AI in healthcare. |
|
|---|
|
|
|
Tuesday, July 25, 2023 1pm ET / 10am PT New methods in scalable compute cloud environments not only accelerate drug discovery in a cost-effective manner, but benefit from reduced deployment time, accelerated GPU speed, and reduced infrastructure costs. Register now to learn more. 
|
|
Whitepaper Leading facilities practices and technologies can help improve the productivity of your research and manufacturing operations—and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
Research The right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
eBook This eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Take a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
